Evidence map›Paper›PMID 30742812›Full record

ReviewJournal of molecular and cellular cardiology2019

PKC and PKN in heart disease.

Valeria Marrocco, Julius Bogomolovas, Elisabeth Ehler, Cristobal G Dos Remedios, Jiayu Yu, Chen Gao, Stephan Lange

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of molecular and cellular cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Loss of phospholamban phosphorylation blunts CaJournal of molecular and cellular cardiology · 2026
    Article
  3. Article
  4. Article
  5. TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.Cardiovascular & hematological agents in medicinal chemistry · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 6 countries.

Valeria MarroccoDivision of Cardiology, School of Medicine, University of California-San Diego, La Jolla, USA.
Julius BogomolovasDivision of Cardiology, School of Medicine, University of California-San Diego, La Jolla, USA; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Elisabeth EhlerRandall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, School of Cardiovascular Medicine and Sciences, British Heart Foundation Research Excellence Centre, King's College London, New Hunt's House, Guy's Campus, London SE1 1UL, UK.
Cristobal G Dos RemediosBosch Institute, Department of Anatomy, University of Sydney, Sydney. Australia.
Jiayu YuKey Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen GaoDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, USA. Electronic address: gaochen0813@ucla.edu.
Stephan LangeDivision of Cardiology, School of Medicine, University of California-San Diego, La Jolla, USA; University of Gothenburg, Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg, Sweden. Electronic address: slange@ucsd.edu.
University of California San Diego · USHeidelberg University · DEKing's College London · GBShanghai Jiao Tong University · CNThe University of Sydney · AUUniversity of California, Los Angeles · US

Funding

The role of obscurin and Obsl1 as key determinants for diastolic functionR01HL152251 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHO, YOSHITAKE, LANGE, STEPHAN · 2021 to 2024
$2.3M
Signaling Pathways in Dilated CardiomyopathyR01HL128457 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LANGE, STEPHAN · 2015 to 2019
$1.9M
Cullin mediated protein turnover in skeletal and cardiac musclesR00HL107744 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LANGE, STEPHAN · 2013 to 2015
$726k
Cullin mediated protein turnover in skeletal and cardiac musclesK99HL107744 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LANGE, STEPHAN · 2011 to 2012
$178k
British Heart Foundation RE/13/2/30182Medical Research Council MR/R017050/1NHLBI NIH HHS K99 HL107744NHLBI NIH HHS R00 HL107744NHLBI NIH HHS R01 HL128457NHLBI NIH HHS R01 HL152251
6 · The paper itself

Abstract

The protein kinase C (PKC) and closely related protein kinase N (PKN) families of serine/threonine protein kinases play crucial cellular roles. Both kinases belong to the AGC subfamily of protein kinases that also include the cAMP dependent protein kinase (PKA), protein kinase B (PKB/AKT), protein kinase G (PKG) and the ribosomal protein S6 kinase (S6K). Involvement of PKC family members in heart disease has been well documented over the years, as their activity and levels are mis-regulated in several pathological heart conditions, such as ischemia, diabetic cardiomyopathy, as well as hypertrophic or dilated cardiomyopathy. This review focuses on the regulation of PKCs and PKNs in different pathological heart conditions and on the influences that PKC/PKN activation has on several physiological processes. In addition, we discuss mechanisms by which PKCs and the closely related PKNs are activated and turned-off in hearts, how they regulate cardiac specific downstream targets and pathways, and how their inhibition by small molecules is explored as new therapeutic target to treat cardiomyopathies and heart failure.

Indexed as

Cyclic AMP-Dependent Protein KinasesHeart DiseasesHumansMyocardiumProtein Kinase CProto-Oncogene Proteins c-aktSignal TransductionCyclic AMP-Dependent Protein KinasesProtein Kinase Cprotein kinase NProto-Oncogene Proteins c-aktCardiomyopathyKinasePhosphorylationPKCPKN

Identifiers

PMID30742812
PMCPMC6408329
OpenAlexW2914197299

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.